Featured Research

from universities, journals, and other organizations

New prostate cancer treatment convenient, less expensive, but may be riskier

Date:
March 10, 2014
Source:
Yale University
Summary:
A faster and less expensive form of radiotherapy for treating prostate cancer may come at a price, according to a new study -- a higher rate of urinary complications. "While these data are by no means definitive, our findings emphasize the need to carefully assess the impact of new cancer treatment technologies in actual practice," reported the authors.

A faster and less expensive form of radiotherapy for treating prostate cancer may come at a price, according to a new study by Yale School of Medicine researchers -- a higher rate of urinary complications.

Related Articles


The standard external beam radiation therapy for prostate cancer is called intensity modulated radiation therapy (IMRT). Stereotactic body radiotherapy (SBRT) is a newer treatment that delivers a greater dose of radiation per treatment than IMRT. As a result, patients receiving SBRT can complete an entire course of treatment in one to two weeks, compared to seven to nine weeks for IMRT. There have been few studies comparing the costs of these treatments, and their toxicity.

This new study -- published in the March 10 Journal of Clinical Oncology by researchers at the Cancer Outcomes, Public Policy and Effectiveness Research (COPPER) Center at Yale Cancer Center -- compared IMRT to SBRT in a national sample of 4,005 Medicare patients age 66 and older receiving prostate cancer treatment. Participants received either SBRT or IMRT as a primary treatment for prostate cancer during 2008 to 2011.

"All the reports we have about the toxicity of SBRT comes from pioneering institutions," said first author James Yu, M.D., assistant professor of therapeutic radiology at Yale Cancer Center. "But now that SBRT is being used nationally, it is important to determine the costs and complications on a national level."

Yu, senior author Cary Gross, M.D., and their colleagues found that the mean per-patient cost to Medicare for a course of SBRT was about $13,600, compared to $21,000 for IMRT. The team found that at 24 months after the start of the treatment, there were increased side effects for SBRT compared to IMRT, due to urethral irritation, urinary incontinence, and obstruction. However, even when including the cost of treating complications, the overall medical costs due to SBRT were still lower than that of IMRT.

"While these data are by no means definitive, our findings emphasize the need to carefully assess the impact of new cancer treatment technologies in actual practice," said Gross, professor of internal medicine at Yale School of Medicine, and director of the Yale COPPER Center at Yale Cancer Center.


Story Source:

The above story is based on materials provided by Yale University. Note: Materials may be edited for content and length.


Journal Reference:

  1. J. B. Yu, L. D. Cramer, J. Herrin, P. R. Soulos, A. L. Potosky, C. P. Gross. Stereotactic Body Radiation Therapy Versus Intensity-Modulated Radiation Therapy for Prostate Cancer: Comparison of Toxicity. Journal of Clinical Oncology, 2014; DOI: 10.1200/JCO.2013.53.8652

Cite This Page:

Yale University. "New prostate cancer treatment convenient, less expensive, but may be riskier." ScienceDaily. ScienceDaily, 10 March 2014. <www.sciencedaily.com/releases/2014/03/140310161554.htm>.
Yale University. (2014, March 10). New prostate cancer treatment convenient, less expensive, but may be riskier. ScienceDaily. Retrieved November 27, 2014 from www.sciencedaily.com/releases/2014/03/140310161554.htm
Yale University. "New prostate cancer treatment convenient, less expensive, but may be riskier." ScienceDaily. www.sciencedaily.com/releases/2014/03/140310161554.htm (accessed November 27, 2014).

Share This


More From ScienceDaily



More Health & Medicine News

Thursday, November 27, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Ebola Leaves Orphans Alone in Sierra Leone

Ebola Leaves Orphans Alone in Sierra Leone

AFP (Nov. 27, 2014) — The Ebola epidemic sweeping Sierra Leone is having a profound effect on the country's children, many of whom have been left without any family members to support them. Duration: 01:02 Video provided by AFP
Powered by NewsLook.com
Experimental Ebola Vaccine Shows Promise In Human Trial

Experimental Ebola Vaccine Shows Promise In Human Trial

Newsy (Nov. 27, 2014) — A recent test of a prototype Ebola vaccine generated an immune response to the disease in subjects. Video provided by Newsy
Powered by NewsLook.com
Pet Dogs to Be Used in Anti-Ageing Trial

Pet Dogs to Be Used in Anti-Ageing Trial

Reuters - Innovations Video Online (Nov. 26, 2014) — Researchers in the United States are preparing to discover whether a drug commonly used in human organ transplants can extend the lifespan and health quality of pet dogs. Video provided by Reuters
Powered by NewsLook.com
Today's Prostheses Are More Capable Than Ever

Today's Prostheses Are More Capable Than Ever

Newsy (Nov. 26, 2014) — Advances in prosthetics are making replacement body parts stronger and more lifelike than they’ve ever been. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins